Silence Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Silence Therapeutics (SLN).

Price Target Range — 11 Quarters

Analyst Consensus — 6 Analysts

5Buy

1Sell

Consensus RatingBuy# Analysts6Avg. Consensus PT$41Upside to Avg. PT+108.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 11, 2026	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$25→$32
Jun 24, 2026	Cantor Fitzgerald	Prakhar Agrawal	Initiate	Overweight	—
Jun 17, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$75
Mar 13, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$75
Sep 16, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$75
Aug 8, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$35
Jun 13, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$75
Jun 13, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$35
May 9, 2025	Goldman Sachs	Richard Law	PT Cut	Sell	$4→$3
May 9, 2025	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$45→$25
May 9, 2025	Chardan Capital	Keay Nakae	PT Cut	Buy	$55→$35
Mar 7, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$75
Mar 5, 2025	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$49→$45
Mar 4, 2025	BMO Capital	Kostas Biliouris	PT Cut	Outperform	$67→$25
Mar 4, 2025	Goldman Sachs	Richard Law	PT Cut	Sell	$6→$4
Feb 11, 2025	Goldman Sachs	Richard Law	Initiate	Sell	$6
Feb 3, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$75
Jan 29, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$75
Dec 10, 2024	Chardan Capital	Keay Nakae	Maintained	Buy	$55
Dec 9, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$75

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target from $25 to $32.

Benzinga Newsdesk

This $300 Million Biotech May Be Deeply Mispriced: Analyst

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major catalyst in the PV market.

Vandana Singh

PRO
Cantor Fitzgerald Initiates Coverage On Silence Therapeutics with Overweight Rating

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Silence Therapeutics (NASDAQ:SLN) with a Overweight rating.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.

Benzinga Newsdesk

Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran's profile against rusfertide.

Vandana Singh

PRO
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.

Benzinga Newsdesk

Silence Therapeutics PLC

뉴스

파트너 / 기고자

벤징가 글로벌

Silence Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32

This $300 Million Biotech May Be Deeply Mispriced: Analyst

PRO
Cantor Fitzgerald Initiates Coverage On Silence Therapeutics with Overweight Rating

PRO
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

PRO
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

People Also Watch

People Also Watch

Silence Therapeutics PLC

뉴스

파트너 / 기고자

벤징가 글로벌

Silence Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32

This $300 Million Biotech May Be Deeply Mispriced: Analyst

PROCantor Fitzgerald Initiates Coverage On Silence Therapeutics with Overweight Rating

PROHC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

PROHC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32

PRO
Cantor Fitzgerald Initiates Coverage On Silence Therapeutics with Overweight Rating

PRO
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target